Shao Zi'an, Zheng Shuai, Chen Chong, Lyu Jun
The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China.
Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, People's Republic of China.
Int J Gen Med. 2021 Oct 28;14:7317-7327. doi: 10.2147/IJGM.S334071. eCollection 2021.
Cecal adenocarcinoma has a high degree of malignancy and poor prognosis, thereby bringing serious disease burden to patients. The long-term survival rate of patients with cecal adenocarcinoma deserves us to explore more deeply. In addition, appropriate methods that evaluate the survival outcome of cecal adenocarcinoma are few.
This study used the data provided by the Surveillance, Epidemiology, and End Results (SEER) database to evaluate and predict the survival rates of patients with cecal adenocarcinoma from 2002 to 2016 and from 2017 to 2021, respectively. The cohort of population taken are all older than 20 years old, which is from National Cancer Institute. The period analysis was used to check the data in the SEER database. Reliable results could be obtained using period analysis, which provided important information for prevention and treatment strategies.
From 2002 to 2016, the relative survival rate of patients with cecal adenocarcinoma increased yearly. Compared with those in previous 15 years, the relative survival rate between 2017 and 2021 still increased but to a low extent. The relative survival rates of patients with cecal adenocarcinoma were remarkably different in terms of age, sex, race, differentiation grade, stages, and socioeconomic status. Even if there is a significant improvement, the survival rate of patients with distant-stage cancer is at a very low level.
Understanding the survival rate of patients with cecal adenocarcinoma in the past 15 years is helpful in predicting the future trend and providing basic data and scientific basis to evaluate the harm of cecal adenocarcinoma to patients' health, prepare cancer prevention plans, and evaluate the effect of cancer prevention and treatment by exploring the differences in survival rate corresponding to different ages, sexes, races, differentiation grades, stages, and socioeconomic status.
盲肠腺癌恶性程度高、预后差，给患者带来沉重的疾病负担。盲肠腺癌患者的长期生存率值得我们更深入地探索。此外，评估盲肠腺癌生存结局的合适方法较少。
本研究利用监测、流行病学和最终结果（SEER）数据库提供的数据，分别评估和预测2002年至2016年以及2017年至2021年盲肠腺癌患者的生存率。选取的人群队列均为20岁以上，来自美国国立癌症研究所。采用期间分析来检查SEER数据库中的数据。使用期间分析可获得可靠结果，为防治策略提供重要信息。
2002年至2016年，盲肠腺癌患者的相对生存率逐年上升。与前15年相比，2017年至2021年的相对生存率仍有上升，但幅度较小。盲肠腺癌患者的相对生存率在年龄、性别、种族、分化程度、分期和社会经济地位方面存在显著差异。即使有显著改善，远处转移癌患者的生存率仍处于非常低的水平。
了解过去15年盲肠腺癌患者的生存率有助于预测未来趋势，并通过探索不同年龄、性别、种族、分化程度、分期和社会经济地位对应的生存率差异，为评估盲肠腺癌对患者健康的危害、制定癌症预防计划以及评估癌症防治效果提供基础数据和科学依据。
